Skip to main content
Back
ROIV logo

Roivant Sciences Ltd.

Data quality: 100%
ROIV
NASDAQ Healthcare Biotechnology
$27.93
▲ $0.23 (0.83%)
Mkt Cap: 19.99B
Day Range
$27.66 $28.39
52-Week Range
$8.73 $30.33
Volume
4,814,209
50D / 200D Avg
$25.80 / $18.18
Prev Close
$27.70

Price History

Financial Trends

Peer Comparison

vs Healthcare sector median (625 peers)

Metric Stock Sector Median
P/E -116.2 14.0
P/B 4.3 2.4
ROE % -3.2 11.4
Net Margin % -592.0 10.1
Rev Growth 5Y % 5.1 7.0
D/E 0.0 0.5

Key Takeaways

Revenue grew 5.12% annually over 5 years — modest growth
Earnings declined -103.95% over the past year
Debt/Equity of 0.02 — conservative balance sheet
Negative free cash flow of -844.05M
PEG of 0.41 suggests growth is underpriced
Revenue growth is decelerating — 1Y growth trails 5Y average by 16.31%

Growth

Revenue Growth (5Y)
5.12%
Revenue (1Y)-11.19%
Earnings (1Y)-103.95%
FCF Growth (3Y)N/A

Quality

Return on Equity
-3.23%
ROIC-15.72%
Net Margin-591.96%
Op. Margin-3453.32%

Safety

Debt / Equity
0.02
Current Ratio33.47
Interest Coverage0.00

Valuation

P/E Ratio
-116.23
P/B Ratio4.26
EV/EBITDAN/A
Dividend Yield0.00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) -11.19% Revenue Growth (3Y) -31.14%
Earnings Growth (1Y) -103.95% Earnings Growth (3Y) N/A
Revenue Growth (5Y) 5.12% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 29.05M Net Income (TTM) -171.98M
ROE -3.23% ROA -3.16%
Gross Margin 96.86% Operating Margin -3453.32%
Net Margin -591.96% Free Cash Flow (TTM) -844.05M
ROIC -15.72% FCF Growth (3Y) N/A
Safety
Debt / Equity 0.02 Current Ratio 33.47
Interest Coverage 0.00 Dividend Yield 0.00%
Valuation
P/E Ratio -116.23 P/B Ratio 4.26
P/S Ratio 688.04 PEG Ratio 0.41
EV/EBITDA N/A Dividend Yield 0.00%
Market Cap 19.99B Enterprise Value 17.37B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2024 FY2023 FY2022 FY2021 FY2020
Revenue 29.05M 32.71M 61.28M 55.29M 23.80M
Net Income -171.98M 4.35B -1.01B -845.26M -809.23M
EPS (Diluted) -0.24 5.23 -1.42 -1.26 -1.18
Gross Profit 28.14M 31.11M 48.15M 46.32M 21.74M
Operating Income -1.00B 4.50B -1.18B -1.35B -1.07B

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2024 FY2023 FY2022 FY2021 FY2020
Total Assets 5.44B 7.22B 2.39B 2.59B 2.69B
Total Liabilities 249.74M 773.95M 782.02M 523.70M 527.69M
Shareholders' Equity 4.69B 5.97B 1.16B 1.66B 1.90B
Total Debt 100.17M 499.75M 481.40M 283.89M 244.98M
Cash & Equivalents 2.72B 6.54B 1.68B 2.06B 2.13B
Current Assets 5.00B 6.73B 1.80B 2.15B 2.19B
Current Liabilities 149.41M 266.76M 272.45M 184.37M 218.96M